Jane Liesveld, MD
Hematology · Rochester, NYNPI 1851319610
Payments from drug & device makers
Across 258 payments — averaging $5642.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$448K
- Pfizer$430K
- Taiho Oncology, Inc.$191K
- Otsuka Pharmaceutical Co., Ltd.$95K
- Janssen Research & Development, LLC$58K
- Incyte Corporation$55K
- plus $178K from 17 others
Across 12 payments — averaging $4993.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$60K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $448,488 |
| Pfizer | 16 | $429,771 |
| Taiho Oncology, Inc. | 12 | $191,030 |
| Otsuka Pharmaceutical Co., Ltd. | 4 | $95,027 |
| Janssen Research & Development, LLC | 3 | $58,323 |
| Incyte Corporation | 49 | $55,479 |
| Syndax Pharmaceuticals, Inc. | 2 | $36,046 |
| Bristol Myers Squibb | 8 | $35,647 |
| Daiichi Sankyo Inc. | 38 | $21,184 |
| Servier Pharmaceuticals LLC | 20 | $20,101 |
| Novartis | 3 | $16,728 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $14,775 |
| Sanofi US Services Inc. | 3 | $12,076 |
| Merck | 9 | $6,500 |
| National Marrow Donor Program | 13 | $5,000 |
| Blueprint Medicines Corporation | 1 | $2,633 |
| Kadmon Corporation LLC | 3 | $2,197 |
| Pharmacosmos Therapeutics Inc. | 1 | $1,500 |
| CTI Biopharma Corp. | 1 | $1,272 |
| Sobi, Inc | 1 | $1,170 |
| Jazz Pharmaceuticals Inc. | 5 | $597 |
| Gilead | 1 | $112 |
| Biolinerx USA, Inc. | 1 | $50 |
How this compares
$1,455,704 in reported general payments places this provider in the 90th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Rochester
- Paul BarrRochester$47.3M
- Carla CasuloRochester$2.9M
- Kristen O DwyerRochester$1.9M
- Ajay DhakalRochester$658K
- Andrew EvansRochester$615K
- Jainulabdeen IfthikharuddinRochester$429K
- Deborah MulfordRochester$402K
- Jason MendlerRochester$294K
- Jonathan FriedbergRochester$231K
- Alissa HustonRochester$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.